Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)

被引：0
|
作者：
Chen, CI
White, D
Kouroukis, CT
Stewart, AK
Howson-Jan, K
Larratt, L
Powers, J
Eisenhauer, E
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] QE II Hlth Sci Ctr, Halifax, NS, Canada
[3] Margaret & Charles Juravinski Canc Ctr, Hamilton, ON, Canada
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada
[6] Natl Canc Inst, Clin Trials Grp, Kingston, ON, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3288
引用
下载
收藏
页码：896A / 896A
页数：1
相关论文
共 50 条
  • [1] The proteasome inhibitor bortezomib (PS-341) is active against Waldenstrom's macroglobulinemia (WM).
    Mitsiades, CS
    Mitsiades, N
    McMullan, CJ
    Poulaki, V
    Shringarpure, R
    Hideshima, T
    Chauhan, D
    Treon, SP
    Richardson, PG
    Munshi, NC
    Joseph, M
    Libermann, TA
    Anderson, KC
    BLOOD, 2003, 102 (11) : 181A - 181A
  • [2] Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM.
    Chen, C. I.
    Kouroukis, T.
    White, D.
    Voralia, M.
    Stadtmauer, E.
    Wright, J.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 432S - 432S
  • [3] A phase II trial of the proteosome inhibitor PS-341 (Bortezomib; Velcade)in patients with metastatic colorectal cancer.
    Mackay, HJ
    Major, P
    Townsley, C
    Mackenzie, M
    Vincent, M
    Boudreau, T
    Tsao, M
    Hedley, D
    Wright, J
    Siu, L
    Moore, M
    Oza, AM
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6201S - 6201S
  • [4] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
  • [5] Rituximab for Waldenstrom's macroglobulinemia (WM) (E3A98): An ECOG phase II pilot study for untreated or previously treated patients.
    Gertz, MA
    Rue, M
    Blood, E
    Kaminer, LS
    Vesole, DH
    Greipp, PR
    BLOOD, 2003, 102 (11) : 148A - 148A
  • [6] Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (02): : 79 - 82
  • [7] PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
    Oakervee, HE
    Popat, R
    Curry, N
    Smith, P
    Morris, C
    Drake, M
    Agrawal, S
    Stec, J
    Schenkein, D
    Esseltine, DL
    Cavenagh, JD
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) : 755 - 762
  • [8] Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
    Shah, MH
    Young, D
    Kindler, HL
    Webb, I
    Kleiber, B
    Wright, J
    Grever, M
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6111 - 6118
  • [9] Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia
    Ghobrial, Irene M.
    Padmanabhan, Swaminathan
    Badros, Ashraf Z.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    Treon, Steven
    Matous, Jeffrey
    BLOOD, 2009, 114 (22) : 1444 - 1444
  • [10] PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma.
    Cavenagh, JD
    Popat, R
    Curry, N
    Stec, J
    Morris, TC
    Drake, M
    Agrawal, S
    Smith, P
    Schenkein, DP
    Esseltine, DL
    Oakervee, H
    BLOOD, 2004, 104 (11) : 413A - 413A
12345